14

General Information


DRACP ID  DRACP01958

Peptide Name   14

Sequence  GLWGVIKALGGHVG

Sequence Length  14

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane-targeted



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A549 Lung adenocarcinoma Carcinoma EC50>100 μM MTT assay 24 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01958

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C64H102N18O15

Absent amino acids  CDEFMNPQRSTY

Common amino acids  G

Mass  159571

Pl  9.7

Basic residues  2

Acidic residues  0

Hydrophobic residues  7

Net charge  2

Boman Index  2147

Hydrophobicity  87.86

Aliphatic Index  132.14

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  5500

Absorbance 280nm  423.08

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 30953170

Title  De novo design of anticancer peptides by ensemble artificial neural networks

Doi 10.1007/s00894-019-4007-6

Year  2019

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_13160

DRACP is developed by Dr.Zheng's team.